Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 8/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 2/20 | 0.42 |
| ▸ | SKP1 | P63208 | 2/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17447170 | 0.90 | PDE4B (0.42) | KHKCNR2 | |
| SCHEMBL17439549 | 0.85 | KHK (0.61) | KHK | |
| SCHEMBL17439506 | 0.85 | KHK (0.49) | KHK | |
| SCHEMBL17439501 | 0.81 | KHK (0.49) | KHK | |
| SCHEMBL17439616 | 0.79 | KHK (0.46) | KHK | |
| SCHEMBL17447239 | 0.78 | PDE4B (0.42) | CNR2GPR119 | |
| SCHEMBL17447169 | 0.75 | PDE4B (0.42) | CNR2 | |
| SCHEMBL2549633 | 0.75 | KHK (0.68) | KHK | |
| SCHEMBL17447237 | 0.75 | KHK (0.54) | KHK | |
| SCHEMBL17447167 | 0.75 | PDE4B (0.57) | KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106660996-B | 2, 5-substituted pyrimidines as PDE4 inhibitors | 格吕伦塔尔有限公司 | 2020-10-16 | — | — | CN | disclosed |
| US-10391099-B2 | Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| EP-3415510-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS | Grünenthal GmbH (DE) | 2018-12-19 | — | — | EP | disclosed |
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| US-9546158-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | KHK 1537/4885CNR2 1478/4885CKS1B 1145/4885 |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | KHK 1537/4885CNR2 1478/4885CKS1B 1145/4885 |
| US-10391099-B2 | Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | KHK 1526/4885CNR2 1492/4885CKS1B 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.